7Baggers

Immuneering Quarterly Cash Flow Statements Chart

Quarterly
 | 
Annual
 
 Operating Cashflow  
 Investing Cashflow  
 Financing Cashflow  
 Capital Expenditure  
20210630 20210930 20211231 20220331 20220630 20220930 20221231 20230331 20230630 20230930 20231231 -52.77-28.31-3.8420.6345.0969.5694.02118.49Milllion

Immuneering Quarterly Cash Flow Statements Table

Quarterly
 | 
Annual
 
Unit: USD2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 
  net cash from operating activities-11,775,201 -12,026,932 -10,748,483 -14,418,018 -11,748,614 -10,622,339 -9,449,273 -12,281,039 -9,238,990 -9,034,629 -6,437,423 
  net cash from investing activities3,132,919 -23,971,748 9,163,314 18,972,007 8,152,327 -880,076 22,153,908 12,404,843 -22,807,934 -52,771,645 -19,824 
  net cash from financing activities7,835 21,448 28,172,382 239,408 -184,677 -17,214 27,784 193,111 7,519 118,488,721 25,768,603 
  capital expenditure-170,918 -57,149 -86,686 -27,993 -69,302 -393,134 -164,997 -115,050 -13,052 -11,346 -19,824 

We provide you with 20 years of cash flow statements for Immuneering stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Immuneering stock. Explore the full financial landscape of Immuneering stock with our expertly curated income statements.

The information provided in this report about Immuneering stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.